ASCO Aug 17, 2022 Oncologists Consider Germline Testing in Lung Cancer Patients Amid New Data Showing High Prevalence Premium Aug 16, 2022 Gilead Sciences Files for Trodelvy FDA Approval in HR-Positive Breast Cancer, Buys Rights in Asia Aug 8, 2022 CAP Weighs in on dMMR, MSI Assays for Immunotherapy Patient Selection Premium Aug 1, 2022 OriCell Therapeutics Raises $120M in Series B Round Jul 29, 2022 AstraZeneca Q2 Oncology Sales Grow 14 Percent as Firm Awaits Key Precision Drug Regulatory Decisions Premium Jul 19, 2022 Kisqali Shines as Novartis Posts Slight Decline in Q2 Revenues Jun 22, 2022 Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer Premium Jun 16, 2022 Janssen Hoping to Bring Tissue-Agnostic Data on Balversa to Regulators Next Year Premium Jun 9, 2022 Sophia Genetics, GE Healthcare Begin DEEP-Lung-IV Data Collection, Technology Integration Premium Jun 9, 2022 Yondelis Fails to Improve Survival in BRCA1/2-Mutant Ovarian Cancer in Phase III ASCO Study Jun 8, 2022 Biomarker-Defined Subset of Early Breast Cancer Patients Can Avoid Radiation, ASCO Data Show Jun 8, 2022 Oncology Pharmacist Helps Boost Patient Enrollment at Community Practices Engaging in MYLUNG Study Jun 8, 2022 New Data Suggests Liquid Biopsy Provides Early ID of Breast Cancer Patients Destined to Recur Premium Jun 8, 2022 Merus, Elevation Oncology Drugs Show Initial Activity in Lung, Pancreatic Cancers With NRG1 Fusions Premium Jun 7, 2022 African American Prostate Cancer Patients Get More VUS, Fewer Actionable Results, Studies Show Jun 7, 2022 Circulating Tumor DNA Utility in Post-Surgery Stage II Colon Cancer Cemented by New Data Premium Jun 7, 2022 Mirati Hoping to Set Apart Adagrasib in Competitive KRAS-Mutant NSCLC Market With CNS Activity Data Premium Jun 6, 2022 With ASCO Data, Novartis' Tafinlar-Mekinist Heads Toward FDA for BRAF-Mutant Pediatric Brain Cancer Premium Jun 6, 2022 Oncologists Debate Suitability of CDK4/6 Inhibitors at ASCO Given Long-Term Ibrance Data Premium Jun 6, 2022 VISION Trial Sub-Studies Refine Pluvicto Benefit as Radiopharmaceutical Access Barriers Persist Premium Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
